| HCC | Hepatocellular carcinoma |
| ICI | Immune checkpoint inhibitors |
| TKI | Tyrosine-kinase inhibitors |
| OS | Overall survival |
| ORR | Objective response rate |
| LDT | Liver-directed therapy |
| BCLC | Barcelona Clinic Liver Cancer |
| TACE | Transarterial chemoembolization |
| TARE | Transarterial radioembolization |
| 90Y | Yttrium-90 |
| Atezo | Atezolizumab |
| Bev | Bevacizumab |
| Treme | Tremelimumab |
| Durva | Durvalumab |
| PFS | Progression-free survival |
| CR | Complete response |
| OR | Objective response |
| TTP | Time to progression |
| IQR | Interquartile range |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.